Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

NCT05780073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection Primary

Interventions

DRUG: Dasatinib 70 mg
OTHER: Placebo

Sponsor

Fundació Institut Germans Trias i Pujol

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]